Abstract

The purpose of this study is to examine hematopoietic neoplasms with 9p24/JAK2 rearrangement including neoplasms associated with t(8;9)(p22;p24)/PCM1-JAK2 fusion neoplasm as well as cases with translocations involving 9p24/JAK2 and other partner genes. From seven large medical centers, we identified ten patients with t(8;9)(p22;p24) /PCM1-JAK2 and 3 with t(9p24;v)/JAK2 at diagnosis. Majority of the cases showed myeloproliferative neoplasm (MPN) associated features (n = 7) characterized by variable degrees of eosinophilia, myelofibrosis, frequent proliferations of early erythroblasts in bone marrow and extramedullary sites, and infrequent/absent somatic mutations. Other less common presentations included myelodysplastic syndromes (MDS) or MDS/MPN (one each). Four patients presented with B-lymphoblastic leukemia (B-ALL), and of them, two patients with t(8;9)(p22;p24.1) were proven to be B-lymphoblastic crisis of MPN; and the other two cases with t(9p24;v) both were de novo B-ALL, BCR-ABL1-like (Ph-like). We show that the hematopoietic neoplasms with 9p24/JAK2 rearrangement are extremely rare, and most of them are associated with t(8;9)(p22;p24)/PCM1-JAK2, a recent provisional World Health Organization entity under “myeloid/lymphoid neoplasm with a specific gene rearrangement”. Cases of t(8;9)(p22;p24)/PCM1-JAK2, though heterogeneous, do exhibit some common clinicopathological characteristic features. Cases with t(9p24;v)/JAK2 are extremely rare; while such cases with a MPN presentation may resemble t(8;9)(p22;p24.1)/PCM1-JAK2, B-ALL cases presenting de novo B-ALL might belong to Ph-like B-ALL.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Ihle JN, Gilliland DG. Jak2: normal function and role in hematopoietic disorders. Curr Opin Genet Dev. 2007;17:8–14.

  2. 2.

    Santos FP, Verstovsek S. JAK2 inhibitors: what’s the true therapeutic potential? Blood Rev. 2011;25:53–63.

  3. 3.

    Bain BJ, Ahmad S. Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities? Br J Haematol. 2014;166:809–17.

  4. 4.

    Stewart K, Carstairs KC, Dube ID, Keating A. Neutrophilic myelofibrosis presenting as Philadelphia chromosome negative BCR non-rearranged chronic myeloid leukemia. Am J Hematol. 1990;34:59–63.

  5. 5.

    Reiter A, Walz C, Watmore A, et al. The t(8;9)(p22; p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res. 2005;65:2662–7.

  6. 6.

    Rumi E, Milosevic JD, Selleslag D, et al. Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene. Ann Hematol. 2015;94:1927–8.

  7. 7.

    Bain BJ, Horny H-P, Arber DA, Tefferi A, Hasserjian RP. Myeloid/lymphoid neoplasms with eosinophilia and rearrangements of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Revised. 4th edn. Lyon: International Agency for Research on Cancer (IARC); 2017. p. 72–9.

  8. 8.

    Tang G, Goswami RS, Liang CS, et al. Isolated del(5q) in patients following therapies for various malignancies may not all be clinically significant. Am J Clin Pathol. 2015;144:78–86.

  9. 9.

    Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90:1128–32.

  10. 10.

    Wang SA, Tam W, Tsai AG, et al. Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. Mod Pathol. 2016;29:854–64.

  11. 11.

    Wang SA, Hasserjian RP, Tam W, et al. Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. Haematologica. 2017;102:1352–60.

  12. 12.

    Schwaab J, Knut M, Haferlach C, et al. Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes. Ann Hematol. 2015;94:233–8.

  13. 13.

    Rumi E, Milosevic JD, Casetti I, et al. Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. J Clin Oncol. 2013;31:e269–71.

  14. 14.

    Murati A, Gelsi-Boyer V, Adelaide J, et al. PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation. Leukemia. 2005;19:1692–6.

  15. 15.

    Bousquet M, Quelen C, De Mas V, et al. The t(8;9)(p22; p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene. 2005;24:7248–52.

  16. 16.

    Hidalgo Lopez JE, Carballo-Zarate A, Verstovsek S, et al. Bone marrow findings in blast phase of polycythemia vera. Ann Hematol. 2018;97:425–34.

  17. 17.

    Peeters P, Raynaud SD, Cools J, et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood. 1997;90:2535–40.

  18. 18.

    Zhou MH, Gao L, Jing Y, et al. Detection of ETV6 gene rearrangements in adult acute lymphoblastic leukemia. Ann Hematol. 2012;91:1235–43.

  19. 19.

    Tirado CA, Chen W, Huang LJ, et al. Novel JAK2 rearrangement resulting from a t(9;22)(p24; q11.2) in B-acute lymphoblastic leukemia. Leuk Res. 2010;34:1674–6.

  20. 20.

    Roberts KG, Gu Z, Payne-Turner D, et al. High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. J Clin Oncol. 2017;35:394–401.

  21. 21.

    Reshmi SC, Harvey RC, Roberts KG, et al. Targetable kinase gene fusions in high-risk B-ALL: a study from the Children’s Oncology Group. Blood. 2017;129:3352–61.

  22. 22.

    Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014;371:1005–15.

  23. 23.

    Borowitz MJ, Chan JKC, Downing JR, Le Beau MM, Arber D. B-lymphoblasticleukemia/lymphoma with recurrent genetic abnormalities. In: Swerdlow SH, CE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, editors. WHO classification of Tumors of Haematopoietic and Lymphoid Tissue. Lyon: IARC; 2017.

  24. 24.

    Keane C, Henden A, Mills T, Wood P. Myeloid and lymphoid neoplasm with FGFR1 abnormality. Br J Haematol. 2009;145:440.

  25. 25.

    Wang W, Tang G, Kadia T, et al. Cytogenetic Evolution Associated With Disease Progression in Hematopoietic Neoplasms With t(8;22)(p11; q11)/BCR-FGFR1 Rearrangement. J Natl Compr Canc Netw. 2016;14:708–11.

  26. 26.

    Baer C, Muehlbacher V, Kern W, Haferlach C, Haferlach T. Molecular genetic characterization of myeloid/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2. Haematologica. 2018.

Download references

Author information

Affiliations

  1. Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

    • Guilin Tang
    • , Roberto N. Miranda
    • , Carlos Bueso-Ramos C
    •  & Sa A. Wang
  2. Department of Pathology, University of Chicago, Chicago, IL, USA

    • John Kennedy Sydney Sir Philip
    •  & Daniel A. Arber
  3. Department of Pathology, Boston Children Hospital, Boston, MA, USA

    • Olga Weinberg
  4. Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA

    • Wayne Tam
    • , Elizabeth M. Margolskee
    •  & Attilio Orazi
  5. Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA

    • Sam Sadigh
    • , Jonathan I. Lake
    •  & Adam Bagg
  6. Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH, USA

    • Heesun J. Rogers
    •  & Eric D. Hsi
  7. Department of Pathology, Massachusetts General Hospital, Boston, MA, USA

    • Robert P. Hasserjian

Authors

  1. Search for Guilin Tang in:

  2. Search for John Kennedy Sydney Sir Philip in:

  3. Search for Olga Weinberg in:

  4. Search for Wayne Tam in:

  5. Search for Sam Sadigh in:

  6. Search for Jonathan I. Lake in:

  7. Search for Elizabeth M. Margolskee in:

  8. Search for Heesun J. Rogers in:

  9. Search for Roberto N. Miranda in:

  10. Search for Carlos Bueso-Ramos C in:

  11. Search for Eric D. Hsi in:

  12. Search for Attilio Orazi in:

  13. Search for Robert P. Hasserjian in:

  14. Search for Daniel A. Arber in:

  15. Search for Adam Bagg in:

  16. Search for Sa A. Wang in:

Conflict of interest

The authors declare that they have no conflict of interest.

Corresponding author

Correspondence to Sa A. Wang.

Electronic supplementary material

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/s41379-018-0165-9